A M Nzila

Summary

Publications

  1. ncbi Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites
    A M Nzila
    Kenya Medical Research Institute Wellcome Trust Collaborative Research Program, Wellcome Trust Research Laboratories, Nairobi, UK
    Antimicrob Agents Chemother 44:991-6. 2000
  2. ncbi Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum
    A M Nzila
    Wellcome Trust Research Laboratory, Nairobi, Kenya
    J Infect Dis 181:2023-8. 2000
  3. ncbi Genetic diversity of Plasmodium falciparum parasites from Kenya is not affected by antifolate drug selection
    A M Nzila
    Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, Wellcome Trust Research Laboratories, P O Box 43640, Nairobi, Kenya
    Int J Parasitol 32:1469-76. 2002

Collaborators

Detail Information

Publications3

  1. ncbi Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites
    A M Nzila
    Kenya Medical Research Institute Wellcome Trust Collaborative Research Program, Wellcome Trust Research Laboratories, Nairobi, UK
    Antimicrob Agents Chemother 44:991-6. 2000
    ..The prevalence of the triple mutant DHFR-double mutant DHPS combination may be an operationally useful marker for predicting the effectiveness of PM-SD as a new malaria treatment...
  2. ncbi Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum
    A M Nzila
    Wellcome Trust Research Laboratory, Nairobi, Kenya
    J Infect Dis 181:2023-8. 2000
    ..The data predict a longer useful therapeutic life for CPG/Dap than for PM/SD, and, thus, CPG/Dap is a preferable alternative for treatment of chloroquine-resistant falciparum malaria in sub-Saharan Africa...
  3. ncbi Genetic diversity of Plasmodium falciparum parasites from Kenya is not affected by antifolate drug selection
    A M Nzila
    Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, Wellcome Trust Research Laboratories, P O Box 43640, Nairobi, Kenya
    Int J Parasitol 32:1469-76. 2002
    ..Overall, this study shows that the selection for genes that confer drug resistance is not a factor in reducing the genetic diversity of parasite clones in a patient...